Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Vincent Rajkumar

Showing results (231-240 of 566) with videos related to

Pageof 57
Sort By:
British Journal of Haematology|August 21, 2008
Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myelomaSagar Lonial, Paul G Richardson, Jesús San Miguel, et al.
Blood|June 16, 2011
Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myelomaSumit Madan, Martha Q Lacy, Angela Dispenzieri, et al.
Blood|October 24, 2002
Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosisAnimesh Pardanani, Thomas E Witzig, Georgene Schroeder, et al.
Haematologica|December 7, 2005
Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trialDavid Dingli, S Vincent Rajkumar, Grzegorz S Nowakowski, et al.
Blood|January 31, 2009
Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significanceCeline M Vachon, Robert A Kyle, Terry M Therneau, et al.
American Journal of Hematology|February 18, 2011
Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosisShaji K Kumar, Angela Dispenzieri, Martha Q Lacy, et al.
The American Journal of Gastroenterology|February 11, 2015
Trends and racial/ethnic disparities in gluten-sensitive problems in the United States: findings from the National Health and Nutrition Examination Surveys from 1988 to 2012Rok Seon Choung, Ivo C Ditah, Ashley M Nadeau, et al.
Blood Cancer Journal|March 29, 2025
Carfilzomib prescribing patterns and outcomes for relapsed or refractory multiple myeloma: a real-world analysisSharlene Dong, Rahul Banerjee, Adeel M Khan, et al.
Blood|April 28, 2010
Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white womenOla Landgren, S Vincent Rajkumar, Ruth M Pfeiffer, et al.
Lancet (London, England)|December 27, 2016
Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trialBrian G M Durie, Antje Hoering, Muneer H Abidi, et al.
Pageof 57

Showing results (231-240 of 566) with videos related to

Sort By:
Pageof 57
British Journal of Haematology|August 21, 2008
Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myelomaSagar Lonial, Paul G Richardson, Jesús San Miguel, et al.
Blood|June 16, 2011
Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myelomaSumit Madan, Martha Q Lacy, Angela Dispenzieri, et al.
Blood|October 24, 2002
Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosisAnimesh Pardanani, Thomas E Witzig, Georgene Schroeder, et al.
Haematologica|December 7, 2005
Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trialDavid Dingli, S Vincent Rajkumar, Grzegorz S Nowakowski, et al.
Blood|January 31, 2009
Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significanceCeline M Vachon, Robert A Kyle, Terry M Therneau, et al.
American Journal of Hematology|February 18, 2011
Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosisShaji K Kumar, Angela Dispenzieri, Martha Q Lacy, et al.
The American Journal of Gastroenterology|February 11, 2015
Trends and racial/ethnic disparities in gluten-sensitive problems in the United States: findings from the National Health and Nutrition Examination Surveys from 1988 to 2012Rok Seon Choung, Ivo C Ditah, Ashley M Nadeau, et al.
Blood Cancer Journal|March 29, 2025
Carfilzomib prescribing patterns and outcomes for relapsed or refractory multiple myeloma: a real-world analysisSharlene Dong, Rahul Banerjee, Adeel M Khan, et al.
Blood|April 28, 2010
Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white womenOla Landgren, S Vincent Rajkumar, Ruth M Pfeiffer, et al.
Lancet (London, England)|December 27, 2016
Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trialBrian G M Durie, Antje Hoering, Muneer H Abidi, et al.
Pageof 57